PreludeDx nets $20M in new funding

2021 02 24 22 29 5379 Breast Cancer 20210224225528 20220322220342

Molecular diagnostics developer PreludeDx has finalized a $20 million funding round. The company will use the funds to further develop a risk assessment tool for women with ductal carcinoma in situ (DCIS).

The financing round was led by Evidity Health Capital and included participation from new and existing investors, according to PreludeDx. In addition, Evidity Health Capital Managing Director Alejandro Sanchez will join PreludeDx's board of directors.

PreludeDx said it would use the funds to support the commercial expansion of its DCISionRT risk assessment test for women with DCIS and to continue development of its radiogenomics platform for early-stage breast cancer and other cancers.

Page 1 of 176
Next Page